Cradle

Cradle.bio is building AI to design better proteins, faster. Based in Amsterdam, they've cracked into Series B—which means someone with deep pockets and deeper conviction bet on their wet lab meets machine learning approach. Protein engineering is one of those industries that sounds boring until you realize every drug, enzyme, and biologic antibody rolling off production lines started as a folding problem humans couldn't solve without years of trial and error. Cradle's bet: AI cuts that timeline dramatically.

They're operating in the biotech space where the winners aren't necessarily the loudest—they're the ones who actually get molecules to behave in ways nature never intended. The Netherlands has been quietly building a reputation for life sciences infrastructure, and Cradle.bio is positioning themselves as Amsterdam's answer to the protein design problem.